Myocardial infarction, commonly known as heart attack, occurs due to reduced blood flow to a part of the heart, causing damage to the heart muscle. The medications, which are used to treat heart attacks are known as myocardial infarction drugs. The reduced blood flow further causes blockage in the supply of oxygen to the heart, which is due to atherosclerosis, a process in which the plaque is formed on the inside wall of the coronary vein or one of its minor branches. Myocardial infraction occurs to individuals with risk factors such as diabetes, dyslipidemia, and smoking.
Major factors that drive the market growth are growth in incidences of cardiovascular diseases as well as hypertension, diabetes, and obesity. However, stringent regulatory policies by governing bodies coupled with high cost of clinical trials impede the market growth. Moreover, the advancements in technology and the increase in acceptance of newer treatment technologies create lucrative opportunities for key market players especially in untapped economies.
The global myocardial infarction market is segmented based on product type, distribution channel, and region. Based on product, the market is divided into analgesics (morphine sulfate), antiplatelet agents (aspirin, vorapaxar, and clopidogre), vasodilators (nitroglycerin), thrombolytics (tenecteplase and alteplase [t-PA]), anti-thrombotic agents (heparin, bivalirudin, and enoxaparin. Glycoprotein IIb/IIIa inhibitors abciximab, tirofiban, and eptifibatide), glycoprotein IIb/IIIa inhibitors, B adrenergic blockers (metoprolol and esmolol), angiotensin receptor blockers (candesartan and valsartan), and angiotensin converting enzyme inhibitors (enalapril, captopril, and lisinopril). By distribution channel, the market is classified into hospital pharmacies, hospitals, drug stores, and online drug stores. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players, such as Astrazeneca plc, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi SA, Pfizer Inc., Bayer AG, Novartis International AG, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, and Eli Lilly & Company are also provided in this report.
- This report provides an extensive analysis of the current and emerging trends and dynamics in the global myocardial infarction market.
- In-depth analysis is done by constructing market estimations for the key market segments between 2016 and 2023 to identify the prevailing market opportunities.
- This study evaluates the competitive landscape and value chain to understand the competitive environment across the geographies.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Comprehensive analysis of all regions is provided to determine the prevailing opportunities in these geographies.
Myocardial Infarction Drugs Market Key Segments:
By Product Type
- Morphine sulfate
- Antiplatelet Agents
- Alteplase (t-PA)
- Anti-Thrombotic Agents
- Glycoprotein IIb/IIIa Inhibitors
- Adrenergic Blockers
- Angiotensin Receptor Blockers
- Angiotensin Converting Enzyme Inhibitors
By Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Online Drug Stores
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA